logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Sumitomo Pharma Oncology, Inc.


USPTO Granted Patents = 11



Forward Citations = 12

Loading Chart...
Loading Chart...

29 inventors (with patents filed for the assignee):

goldMedal Adam Siddiqui-Jain (8 out of 25 patents)

silverMedal Steven L Warner (6 out of 36 patents)

bronzeMedal David J Bearss (6 out of 50 patents)

4.  Paul Flynn (4 out of 7 patents)

5.  Jason Marc Foulks (2 out of 7 patents)

6.  Hirotaka Kurebayashi (2 out of 8 patents)

7.  Takahiko Hashizuka (2 out of 4 patents)

8.  Clifford J Whatcott (2 out of 9 patents)

9.  Yuka Arikawa (2 out of 4 patents)

10.  Shuji Masumoto (2 out of 8 patents)

11.  Hiroaki Tanaka (2 out of 38 patents)

12.  Hitoshi Ban (1 out of 37 patents)

13.  Seiji Kamioka (1 out of 14 patents)

14.  Yusuke Sawayama (1 out of 7 patents)

15.  Chiang Jia Li (1 out of 57 patents)


11 patents:

1. 12338261 - Alvocidib prodrugs having increased bioavailability (2025-06-24),
2. 12077554 - CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer (2024-09-03),
3. 11793802 - Treatment of acute myeloid leukemia (AML) with venetoclax failure (2023-10-24),
4. 11746103 - ALK-5 inhibitors and uses thereof (2023-09-05),
5. 11712433 - Compositions comprising PKM2 modulators and methods of treatment using the same (2023-08-01),
6. 11530231 - CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer (2022-12-20),
7. 11529350 - Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof (2022-12-20),
8. 11497756 - Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib (2022-11-15),
9. 11471456 - Formulations comprising heterocyclic protein kinase inhibitors (2022-10-18),
10. 11414394 - Process for producing a hydrate of a hydrochloride salt of 2,2'-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid (2022-08-16),
11. 11400091 - AXL kinase inhibitors and use of the same (2022-08-02),
Sumitomo Pharma Oncology, Inc. is a subsidiary of Sumitomo Dainippon Pharma Co., Ltd., dedicated to developing innovative oncology drugs. With a focus on precision medicine and breakthrough therapies, we aim to improve outcomes for cancer patients worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

11 Patents

#189 in Cambridge, MA

#1,615 in Massachusetts

#26,743 in US

#50,237 in the World

...
Cambridge, MA, United States of America

Sumitomo Pharma Oncology, Inc.

Forward Citations = 12

29 inventors:

goldMedal Adam Siddiqui-Jain (8 out of 25 patents)

silverMedal Steven L Warner (6 out of 36 patents)

bronzeMedal David J Bearss (6 out of 50 patents)

4.  Paul Flynn (4 out of 7 patents)

5.  Jason Marc Foulks (2 out of 7 patents)

Please report any incorrect information to support@idiyas.com
Loading…